A large retrospective study suggests that S100A2 may have the potential to become a biomarker for predicting pancreatectomy or replication therapy in patients with pancreatic cancer (Jamieson et al., 2011; Bachet et al., 2013). The gene discussed is S100A2; the disease is familial pancreatic carcinoma.